COVID-19 With Convalescent Plasma

NCT ID: NCT04616976

Last Updated: 2020-11-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

78 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-01-01

Study Completion Date

2020-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To clarify the effects of convalescent plasma therapy on SARS-CoV-2 negative conversion rate during hospital stay and 28-day mortality of severe and life-threatening COVID-19 patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Convalescent Plasma Treatment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

convalescent plasma therapy group

the patients received convalescent plasma therapy

convalescent plasma

Intervention Type BIOLOGICAL

convalescent plasma was get from the patients who recovery from COVID-19

Control group

the patients with similar situation without convalescent plasma therapy

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

convalescent plasma

convalescent plasma was get from the patients who recovery from COVID-19

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. \> 18 years of age;
2. laboratory-confirmed diagnosis of COVID-19;
3. respiratory failure requiring advanced respiratory support (i.e. high flow nasal cannula\[HFNC\], noninvasive mechanical ventilation \[NIV\], and invasive mechanical ventilation \[IMV\]).

Exclusion Criteria

* no
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Southeast University, China

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Chun Pan

Dr

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Zhongda Hospital, Southeast University

Nanjing, Jiangsu, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

References

Explore related publications, articles, or registry entries linked to this study.

Pan C, Chen H, Xie J, Huang Y, Yang Y, Du B, Qiu H. The Efficiency of Convalescent Plasma Therapy in the Management of Critically Ill Patients Infected With COVID-19: A Matched Cohort Study. Front Med (Lausanne). 2022 Jun 16;9:822821. doi: 10.3389/fmed.2022.822821. eCollection 2022.

Reference Type DERIVED
PMID: 35783610 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

COVID-19 convalescent plasma

Identifier Type: -

Identifier Source: org_study_id